electroCore, Inc. Announces Departure of JP Errico from the Board of Directors
May 26 2023 - 4:01PM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage
bioelectronic medicine and wellness company, today announced the
resignation of its Founder and former CEO, JP Errico from the Board
of Directors. Mr. Errico will continue as a consultant and
strategic advisor to the Company, focused on supporting the growth
and direction of the wellness and human performance brands,
Truvaga™ and TAC-STIM™.
“We are fortunate that electroCore will continue to benefit from
Mr. Errico’s experience in the neuromodulation industry, his
understanding of the physiology of the vagus nerve, and his
knowledge of the markets and therapeutic mechanisms of our
products, despite his absence from the Board room,”
said Daniel Goldberger, Chief Executive Officer of
electroCore. “He will continue to help advise the Company as it
expands its commercial offerings through direct-to-consumer
initiatives and maturing clinical programs.”
Mr. Peter Cuneo, Chairman of the Board of Directors, continued,
“I would like to recognize and thank Mr. Errico for his
past leadership and contributions to the Company during his tenure
as a founder, member of management and the Board of Directors. His
creativity and drive were imperative to the creation of
non-invasive vagus nerve stimulation and his ongoing service to the
Company will be valued.”
“I am pleased to take on a greater role as an advocate for
science and education as the company explores non-invasive vagus
nerve stimulation for optimizing neurodevelopment and cognitive
function, preserving healthy metabolic function, and improving
general wellbeing,” Mr. Errico said.
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general well-being and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral
statements made by representatives of electroCore may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include, but are not limited to, statements about
electroCore's business prospects and clinical and product
development plans; its pipeline or potential markets for its
technologies; the timing, outcome and impact of regulatory,
clinical and commercial developments; the Company’s business
prospects or other new markets and other statements that are not
historical in nature, particularly those that utilize terminology
such as "anticipates," "will," "expects," "believes," "intends,"
other words of similar meaning, derivations of such words and the
use of future dates. Actual results could differ from those
projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to raise
the additional funding needed to continue to pursue electroCore’s
business and product development plans, the inherent uncertainties
associated with developing new products or technologies, the
ability to commercialize gammaCore™, Truvaga™, and TAC-STIM™, the
potential impact and effects of COVID-19 on the business of
electroCore, electroCore’s results of operations and financial
performance, and any measures electroCore has and may take in
response to COVID-19 and any expectations electroCore may have with
respect thereto, competition in the industry in which electroCore
operates and overall market conditions. Any forward-looking
statements are made as of the date of this press release, and
electroCore assumes no obligation to update the forward-looking
statements or to update the reasons why actual results could differ
from those projected in the forward-looking statements, except as
required by law. Investors should consult all of the information
set forth herein and should also refer to the risk factor
disclosure set forth in the reports and other documents electroCore
files with the SEC available at www.sec.gov.
Contact:Rich CockrellCG
Capital404-736-3838ecor@cg.capital
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2024 to Jul 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2023 to Jul 2024